An eastern Ontario manufacturer at the forefront of Canada’s budding medical marijuana business is trying to find answers after the RCMP seized a shipment of marijuana it had ordered.

The incident highlights the gray legal area in which medical marijuana manufacturers are opening up shop, under Health Canada’s new rules.

Tweed Inc., which became Canada’s first publicly-traded medical marijuana manufacturer on Friday, says the RCMP seized a shipment of pot at the Kelowna airport that the company had bought from a grower licensed under the previous regime.

[ Read Whole Story ]

Tweed Marijuana Inc. announces closing of qualifying transaction

April 3, 2014 - Tweed Marijuana Inc. (TSXV: LWI.H) ("Tweed Marijuana"), formerly LW Capital Pool Inc., today announced that it has closed its qualifying transaction with Tweed Inc. ("Tweed") pursuant to which Tweed completed a reverse takeover transaction with Tweed Marijuana (the "Transaction") and has delivered all materials to the TSX Venture Exchange (the "Exchange") required to satisfy the listing conditions.  Trading in the common shares of Tweed Marijuana is expected to resume on the Exchange at open of markets on Friday April 4, 2014 under the symbol "TWD".

Prior to the Transaction, Tweed Marijuana was a capital pool company as defined in the policies of the Exchange and had not commenced commercial operations and had no assets other than cash.  The Transaction constituted Tweed Marijuana's "Qualifying Transaction", as defined in Exchange policies.

Tweed is a licensed producer of medical marijuana in Canada.  The principal activities of Tweed are the production and sale of marijuana out of its facility in Smiths Falls, Ontario as regulated by the Marihuana for Medical Purposes Regulations. 

Neptune and Aker BioMarine Reach Patent Infringement Settlement and License Agreement

Neptune Technologies & Bioressources Inc. ("Neptune") (NEPT) (NTB.TO), Acasti Pharma Inc. ("Acasti") (ACST) (APO.V), a Neptune subsidiary, and Aker BioMarine AS, Aker BioMarine Antarctic AS and Aker BioMarine Antarctic USA (collectively "AKBM") jointly announce a settlement and license agreement that will result in the dismissal of all AKBM respondents from the on-going ITC investigation brought by Neptune and Acasti, as well as the dismissal of all current lawsuits brought by Neptune against AKBM and companies in its value chain.

Neptune Reports Fiscal 2012 Results

Nutraceutical Net Income Increases by More Than 100%

Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation") (Nasdaq:NEPT - News) (TSX:NTB.TO - News) reports today its consolidated financial results for the fiscal year ended February 29, 2012, announces corporate reorganization and the holding of an earning call.

Fiscal year ended February 29, 2012 Financial Results

Nutraceutical Business Results
    Nutraceutical revenues increased by 15% to a record $19,113,000, for the fiscal year ended February 29, 2012, up from $16,583,000 achieved during the corresponding period ended February 28, 2011.